CD8 alpha + lymphoid dendritic cell differentiated from human hematopoietic stem cell and a method for differentiation
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- 金炫寿
- Publication Date
- 2004-11-03
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The present invention relates to lymphoid dendritic cells differentiated from human hematopoietic stem cells, a method for differentiating lymphoid dendritic cells from human hematopoietic stem cells, and a pharmaceutical composition containing lymphoid dendritic cells as an active ingredient for immunotherapy. Background technique
[0002] Dendritic cells (DCs) are potent antigen-presenting cells (APCs) that coordinate various immune responses against specific antigens and simultaneously suppress autoimmune responses by eliminating potentially autoreactive T cells.
[0003] Murine DCs can be subdivided into at least two distinct subtypes, myeloid DS and lymphoid DCs, based on their anatomical localization, transplantation experiments, and cell surface phenotype. have CD11c + , MHCII + , CD4 + , CD8α - DCs with a cell surface phenotype known as CD8α - Myeloid DC, which can be derived from bone marrow precursor cells, has CD11c + , MHCII + , CD4 ...